Free Trial

Aerovate Therapeutics (AVTE) News Today

Aerovate Therapeutics logo
$10.14 +7.46 (+278.36%)
As of 04/29/2025
Aerovate Therapeutics, Inc. stock logo
Investors Buy Large Volume of Call Options on Aerovate Therapeutics (NASDAQ:AVTE)
Aerovate Therapeutics, Inc. (NASDAQ:AVTE - Get Free Report) was the target of unusually large options trading activity on Monday. Stock investors bought 9,373 call options on the stock. This is an increase of approximately 2,291% compared to the average volume of 392 call options.
Aerovate Therapeutics, Inc. stock logo
Nantahala Capital Management LLC Acquires New Stake in Aerovate Therapeutics, Inc. (NASDAQ:AVTE)
Nantahala Capital Management LLC acquired a new stake in shares of Aerovate Therapeutics, Inc. (NASDAQ:AVTE - Free Report) in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm acquired 482,928 shares of the company's stock, valued at approximately $1,
Aerovate Therapeutics, Inc. stock logo
Aerovate Therapeutics, Inc. (NASDAQ:AVTE) to Issue Dividend of $2.40
Aerovate Therapeutics, Inc. (NASDAQ:AVTE) declared a dividend on Wednesday, April 9th. Shareholders of record on Friday, April 25th will be given a dividend of 2.40 per share on Monday, April 28th. The ex-dividend date is Tuesday, April 29th.
Aerovate Therapeutics, Inc. stock logo
Affinity Asset Advisors LLC Purchases 200,000 Shares of Aerovate Therapeutics, Inc. (NASDAQ:AVTE)
Affinity Asset Advisors LLC raised its stake in shares of Aerovate Therapeutics, Inc. (NASDAQ:AVTE - Free Report) by 33.3% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 800,000 shares of the company's stock afte
Aerovate Therapeutics, Inc. stock logo
Aerovate Therapeutics, Inc. (NASDAQ:AVTE) Shares Bought by ADAR1 Capital Management LLC
ADAR1 Capital Management LLC lifted its holdings in Aerovate Therapeutics, Inc. (NASDAQ:AVTE - Free Report) by 720.7% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 928,016 shares of the company's stock after purchas
Aerovate Therapeutics, Inc. stock logo
Aerovate Therapeutics (NASDAQ:AVTE) Issues Quarterly Earnings Results, Meets Expectations
Aerovate Therapeutics (NASDAQ:AVTE - Get Free Report) announced its quarterly earnings results on Thursday. The company reported ($0.19) earnings per share for the quarter, meeting analysts' consensus estimates of ($0.19).
Aerovate Therapeutics, Inc. stock logo
Aerovate Therapeutics (AVTE) Expected to Announce Quarterly Earnings on Monday
Aerovate Therapeutics (NASDAQ:AVTE) will be releasing earnings before the market opens on Monday, March 24, Financial Modeling Prep reports.
Aerovate Therapeutics, Inc. stock logo
Analysts Offer Predictions for AVTE FY2029 Earnings
Aerovate Therapeutics, Inc. (NASDAQ:AVTE - Free Report) - Research analysts at Wedbush issued their FY2029 EPS estimates for shares of Aerovate Therapeutics in a research report issued to clients and investors on Monday, February 24th. Wedbush analyst L. Chico forecasts that the company will post
Aerovate Therapeutics, Inc. stock logo
Aerovate Therapeutics, Inc. (NASDAQ:AVTE) Short Interest Update
Aerovate Therapeutics, Inc. (NASDAQ:AVTE - Get Free Report) saw a large growth in short interest in the month of January. As of January 31st, there was short interest totalling 4,020,000 shares, a growth of 6.9% from the January 15th total of 3,760,000 shares. Based on an average daily trading volume, of 221,800 shares, the short-interest ratio is presently 18.1 days. Approximately 20.5% of the company's shares are short sold.
Aerovate Therapeutics, Inc. stock logo
Deltec Asset Management LLC Acquires New Stake in Aerovate Therapeutics, Inc. (NASDAQ:AVTE)
Deltec Asset Management LLC bought a new position in Aerovate Therapeutics, Inc. (NASDAQ:AVTE - Free Report) in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 194,124 shares of the company's stock, valued
Aerovate Therapeutics, Inc. stock logo
Aerovate Therapeutics, Inc. (NASDAQ:AVTE) Short Interest Up 35.5% in January
Aerovate Therapeutics, Inc. (NASDAQ:AVTE - Get Free Report) was the recipient of a large increase in short interest in the month of January. As of January 15th, there was short interest totalling 2,520,000 shares, an increase of 35.5% from the December 31st total of 1,860,000 shares. Based on an average trading volume of 768,100 shares, the short-interest ratio is currently 3.3 days. Approximately 12.9% of the shares of the stock are sold short.
Aerovate Therapeutics, Inc. stock logo
Jane Street Group LLC Trims Position in Aerovate Therapeutics, Inc. (NASDAQ:AVTE)
Jane Street Group LLC trimmed its position in shares of Aerovate Therapeutics, Inc. (NASDAQ:AVTE - Free Report) by 86.0% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 17,805 shares of the company's stock after selli
Unusually active option classes on open January 16th
Aerovate Therapeutics, Inc. stock logo
Stock Traders Buy High Volume of Aerovate Therapeutics Call Options (NASDAQ:AVTE)
Aerovate Therapeutics, Inc. (NASDAQ:AVTE - Get Free Report) was the recipient of unusually large options trading activity on Thursday. Traders bought 3,010 call options on the company. This is an increase of approximately 338% compared to the typical volume of 687 call options.
Aerovate Therapeutics, Inc. stock logo
Short Interest in Aerovate Therapeutics, Inc. (NASDAQ:AVTE) Rises By 35.5%
Aerovate Therapeutics, Inc. (NASDAQ:AVTE - Get Free Report) saw a significant increase in short interest in December. As of December 31st, there was short interest totalling 2,520,000 shares, an increase of 35.5% from the December 15th total of 1,860,000 shares. Approximately 12.9% of the shares of the stock are short sold. Based on an average daily trading volume, of 768,100 shares, the days-to-cover ratio is presently 3.3 days.
Aerovate Therapeutics, Inc. stock logo
Short Interest in Aerovate Therapeutics, Inc. (NASDAQ:AVTE) Decreases By 5.3%
Aerovate Therapeutics, Inc. (NASDAQ:AVTE - Get Free Report) was the recipient of a large decrease in short interest during the month of November. As of November 30th, there was short interest totalling 1,790,000 shares, a decrease of 5.3% from the November 15th total of 1,890,000 shares. Currently, 9.1% of the shares of the stock are sold short. Based on an average trading volume of 765,600 shares, the short-interest ratio is currently 2.3 days.
Aerovate Therapeutics, Inc. stock logo
GSA Capital Partners LLP Purchases 287,163 Shares of Aerovate Therapeutics, Inc. (NASDAQ:AVTE)
GSA Capital Partners LLP raised its position in shares of Aerovate Therapeutics, Inc. (NASDAQ:AVTE - Free Report) by 226.8% in the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 413,795 shares of the
Aerovate Therapeutics, Inc. stock logo
Short Interest in Aerovate Therapeutics, Inc. (NASDAQ:AVTE) Declines By 17.3%
Aerovate Therapeutics, Inc. (NASDAQ:AVTE - Get Free Report) was the recipient of a large decrease in short interest during the month of October. As of October 31st, there was short interest totalling 549,800 shares, a decrease of 17.3% from the October 15th total of 665,000 shares. Currently, 2.8% of the shares of the stock are sold short. Based on an average daily volume of 750,300 shares, the short-interest ratio is currently 0.7 days.
Aerovate Therapeutics, Inc. stock logo
Wedbush Forecasts Higher Earnings for Aerovate Therapeutics
Aerovate Therapeutics, Inc. (NASDAQ:AVTE - Free Report) - Analysts at Wedbush boosted their FY2024 EPS estimates for Aerovate Therapeutics in a research note issued to investors on Wednesday, November 13th. Wedbush analyst L. Chico now anticipates that the company will earn ($2.85) per share for
Aerovate Therapeutics Reports Q3 Loss Amid Strategic Shift
Aerovate Therapeutics, Jade Biosciences enter merger agreement
Aerovate Therapeutics and Jade Biosciences Announce Strategic Merger
Aerovate Therapeutics and Jade Biosciences Announce Merger Agreement
Aerovate Therapeutics, Inc. stock logo
Short Interest in Aerovate Therapeutics, Inc. (NASDAQ:AVTE) Declines By 21.4%
Aerovate Therapeutics, Inc. (NASDAQ:AVTE - Get Free Report) was the recipient of a large decline in short interest in October. As of October 15th, there was short interest totalling 665,000 shares, a decline of 21.4% from the September 30th total of 846,500 shares. Based on an average trading volume of 240,000 shares, the short-interest ratio is presently 2.8 days. Currently, 3.4% of the company's stock are sold short.
Aerovate Therapeutics, Inc. stock logo
Aerovate Therapeutics, Inc. (NASDAQ:AVTE) Short Interest Down 20.9% in September
Aerovate Therapeutics, Inc. (NASDAQ:AVTE - Get Free Report) was the recipient of a significant drop in short interest during the month of September. As of September 30th, there was short interest totalling 846,500 shares, a drop of 20.9% from the September 15th total of 1,070,000 shares. Approximately 4.3% of the company's shares are short sold. Based on an average daily volume of 284,900 shares, the short-interest ratio is currently 3.0 days.
Get Aerovate Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for AVTE and its competitors with MarketBeat's FREE daily newsletter.

AVTE Media Mentions By Week

AVTE Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

AVTE
News Sentiment

0.77

0.85

Average
Medical
News Sentiment

AVTE News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

AVTE Articles
This Week

9

1

AVTE Articles
Average Week

Get Aerovate Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for AVTE and its competitors with MarketBeat's FREE daily newsletter.


Related Companies and Tools


This page (NASDAQ:AVTE) was last updated on 4/30/2025 by MarketBeat.com Staff
From Our Partners